Cryoport, Inc. Overview
Pro stress-test →Cryoport is a global provider of innovative products and services to the fast-growing Cell & Gene Therapy industry, enabling the future of medicine for a new era of life sciences. With 50 strategic locations covering the Americas, EMEA and APAC, Cryoport's global platform provides mission-critical bio-logistics, bio-storage, bio-processing, and cryogenic systems to life sciences markets worldwide.
Strategic Profile
Pro stress-test →The company specializes in cryogenic shipping for critical biological materials, supporting the development, clinical testing and commercialization of cell and gene therapies, biologics, vaccines and reproductive medicine, offering end-to-end supply chain management to ensure integrity and viability of temperature-sensitive products. Proprietary assets including the Cryoportal logistics platform, first-to-market ISO 21973 certification, and the newly launched IntegriCell cryopreservation service create switching costs and enable premium pricing.
Competitive Landscape
Pro stress-test →Despite 15% revenue growth, expanding margins, and dominant market position in a market growing 20-25% annually, CYRX trades at substantial discount to life sciences services peers. Main competitors include specialized logistics providers (UPS, FedEx specialized divisions), biotech CROs, and emerging cold-chain startups focused on cell and gene therapy supply chain.
Industry Context
Cryoport, Inc. operates in Temperature-controlled logistics / Cell & Gene Therapy Supply Chain / Life Sciences Services.
Key facts
Founded: 1993 · Headquarters: Nashville, Tennessee, United States · Employees: Not available · Revenue: $170-174M (2025E continuing ops) · Market cap: ~$0.8B